ISPE CEO to Step Down at End of 2014 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ISPE CEO to Step Down at End of 2014


The International Society for Pharmaceutical Engineering (ISPE) has announced that CEO Nancy Berg will leave the Society when her three-year contract is completed at the end of 2014.

During her tenure with ISPE, Berg was responsible for the world’s largest professional society fostering dialog and education on technical, scientific, and regulatory best practices in the pharmaceutical and biotech industries. In a press statement, ISPE identified Berg as the architect of the Society’s ongoing strategic plan, focusing on initiatives related to drug shortages, quality metrics, global manufacturing quality, facility and supply chain issues, and patient experiences in clinical trials. She worked to create synergies between pharmaceutical industry stakeholders, bringing together diverse groups of professionals, regulators, and partner organizations to work on issues of shared concern.

Under Berg’s leadership, ISPE introduced a strategic redirection of focus in Europe and Asia, plans to establish a Washington, DC office in 2014 an office in Washington, DC, and launched the Pharma EXPO tradeshow (3 – 5 November 2014, Chicago), in partnership with PMMI.

Working through the end of 2014, Berg will continue to strengthen the organization, support the Board of Directors as it identifies a new CEO, and establish ISPE’s Washington office, the statement says.

 “ISPE appreciates the strategic and directional work contributed by Nancy Berg. Her efforts have established an essential foundation for ensuring ISPE is a dynamic and relevant driver of value for its Members and the pharmaceutical industry,” says Damian Greene, 2014 Chair of ISPE’s International Board of Directors and Global Network Strategy Lead, Global Manufacturing and Supply at Zoetis, Brussels, Belgium.

The search for ISPE’s CEO is being conducted by Pamela Kaul, president, Association Strategies, Inc.

Source: ISPE

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here